• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

作者信息

Sarafidis Pantelis, Ferro Charles J, Morales Enrique, Ortiz Alberto, Malyszko Jolanta, Hojs Radovan, Khazim Khaled, Ekart Robert, Valdivielso Jose, Fouque Denis, London Gérard M, Massy Ziad, Ruggenenti Petro, Porrini Esteban, Wiecek Andrzej, Zoccali Carmine, Mallamaci Francesca, Hornum Mads

出版信息

Nephrol Dial Transplant. 2020 Oct 1;35(10):1825. doi: 10.1093/ndt/gfz137.

DOI:10.1093/ndt/gfz137
PMID:31397476
Abstract
摘要

相似文献

1
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂对糖尿病合并慢性肾脏病患者的肾脏和心脏保护作用。欧洲肾脏病研究与教育协会（ERA-EDTA）的EURECA-m和DIABESITY工作组的共识声明
Nephrol Dial Transplant. 2020 Oct 1;35(10):1825. doi: 10.1093/ndt/gfz137.
2
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.钠-葡萄糖协同转运蛋白 2 抑制剂和胰高血糖素样肽 1 受体激动剂在糖尿病和慢性肾脏病患者中的肾脏和心脏保护作用。欧洲肾脏学会-欧洲透析和移植学会和欧洲糖尿病研究协会糖尿病工作组的共识声明。
Nephrol Dial Transplant. 2019 Feb 1;34(2):208-230. doi: 10.1093/ndt/gfy407.
3
Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.胰高血糖素样肽-1类似物与钠-葡萄糖协同转运蛋白2抑制剂联合治疗糖尿病肥胖症：真实世界经验
Endocrine. 2017 Jan;55(1):173-178. doi: 10.1007/s12020-016-1125-0. Epub 2016 Sep 30.
4
Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.SGLT2 抑制剂和 GLP-1 受体激动剂的肾脏获益：支持 2 型糖尿病医学管理模式转变的证据。
Int J Mol Sci. 2019 Nov 20;20(23):5831. doi: 10.3390/ijms20235831.
5
Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.用于降低 2 型糖尿病患者心血管疾病风险的药物治疗策略：重点关注 SGLT-2 抑制剂和 GLP-1 受体激动剂。
J Intern Med. 2019 Jul;286(1):16-31. doi: 10.1111/joim.12890. Epub 2019 Mar 19.
6
Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.聚焦坎格列净 300：疗效评价及与其他 SGLT-2 抑制剂和长效 GLP-1 受体激动剂的间接比较。
Expert Rev Clin Pharmacol. 2017 Jun;10(6):633-647. doi: 10.1080/17512433.2017.1318061. Epub 2017 Apr 17.
7
Medical Management of Diabesity: Do We Have Realistic Targets?糖尿病肥胖症的医学管理：我们有现实的目标吗？
Curr Diab Rep. 2017 Jan;17(1):4. doi: 10.1007/s11892-017-0828-9.
8
Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.二甲双胍单药治疗失效的 2 型糖尿病患者换用不同降糖药物的疗效比较：一项系统评价和网状 Meta 分析的随机对照临床试验研究
Diabetes Obes Metab. 2018 Apr;20(4):985-997. doi: 10.1111/dom.13185. Epub 2018 Jan 8.
9
Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂降低 2 型糖尿病成人心血管风险的机制。
Can J Diabetes. 2020 Feb;44(1):93-102. doi: 10.1016/j.jcjd.2019.09.003. Epub 2019 Sep 24.
10
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure.在已患有动脉粥样硬化性心脏病或有充血性心力衰竭风险的患者中，钠-葡萄糖协同转运蛋白 2（SGLT-2）抑制剂与胰高血糖素样肽 1（GLP-1）受体激动剂的差异化适应证。
Metabolism. 2020 Mar;104:154045. doi: 10.1016/j.metabol.2019.154045. Epub 2019 Dec 7.

引用本文的文献

1
Effect of Spherical Adsorptive Carbon Among Chronic Kidney Disease Patients: A Nationwide Cohort Study.球形吸附性碳对慢性肾病患者的影响：一项全国性队列研究。
Int J Environ Res Public Health. 2025 Aug 30;22(9):1365. doi: 10.3390/ijerph22091365.
2
Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study.降糖药物与2型糖尿病患者慢性肾脏病的一级预防：一项真实世界的基层医疗研究
Pharmaceuticals (Basel). 2024 Sep 29;17(10):1299. doi: 10.3390/ph17101299.
3
The prevalence of chronic kidney disease among type 2 diabetes mellitus patients in central South Africa.
中南非 2 型糖尿病患者慢性肾脏病的患病率。
S Afr Fam Pract (2004). 2023 May 29;65(1):e1-e6. doi: 10.4102/safp.v65i1.5663.
4
The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes.钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂、胰高血糖素样肽-1（GLP-1）受体激动剂和肾素-血管紧张素-醛固酮系统（RAAS）阻滞剂对2型糖尿病患者肾损伤的保护作用。
Int Urol Nephrol. 2023 Mar;55(3):617-629. doi: 10.1007/s11255-022-03355-6. Epub 2022 Aug 29.
5
Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction.多囊肾病中钠-葡萄糖协同转运蛋白抑制作用：事实还是虚构
Clin Kidney J. 2022 Jan 31;15(7):1275-1283. doi: 10.1093/ckj/sfac029. eCollection 2022 Jul.